tetano
Editor, Senior Moderator
Sci Rep
. 2022 Dec 27;12(1):22413.
doi: 10.1038/s41598-022-25398-6.
A cross-sectional, multicenter survey of the prevalence and risk factors for Long COVID
Waki Imoto[SUP] 1 2 3 [/SUP], Koichi Yamada[SUP] 1 2 3 [/SUP], Ryota Kawai[SUP] 4 [/SUP], Takumi Imai[SUP] 4 [/SUP], Kengo Kawamoto[SUP] 5 [/SUP], Masato Uji[SUP] 5 [/SUP], Hidenori Kanda[SUP] 6 [/SUP], Minoru Takada[SUP] 7 [/SUP], Yoshiteru Ohno[SUP] 8 [/SUP], Hiroshi Ohtani[SUP] 9 [/SUP], Manami Kono[SUP] 10 [/SUP], Atsuhito Hikiishi[SUP] 10 [/SUP], Yosuke Eguchi[SUP] 10 [/SUP], Hiroki Namikawa[SUP] 11 [/SUP], Tomoya Kawaguchi[SUP] 12 [/SUP], Hiroshi Kakeya[SUP] 13 14 15 16 [/SUP]
Affiliations
Abstract
Long-term sequelae of the coronavirus disease (COVID-19) constitute Long COVID. Although Long COVID has been reported globally, its risk factors and effects on quality of life (QOL) remain unclear. We conducted a cross-sectional study using questionnaires and electronic medical records of COVID-19 patients who were diagnosed or hospitalized at five facilities in Japan. Responses were obtained from 285 out of 1,150 patients. More than half of the participants reported Long COVID symptoms of varying severity 1 year after COVID-19. Common sequelae included fatigue, dyspnea, alopecia, concentration problems, memory problems, sleeplessness, and joint pain, which often significantly reduced their QOL. COVID-19 severity was strongly associated with sputum production, chest pain, dyspnea, sore throat, and diarrhea, but not with fatigue, dysgeusia, anosmia, alopecia, and sleeplessness. Fatigue, dysgeusia, anosmia, alopecia, and sleeplessness affected the QOL among participants with asymptomatic or mild COVID-19 during the acute phase. Moreover, these sequelae persisted for prolonged periods.
. 2022 Dec 27;12(1):22413.
doi: 10.1038/s41598-022-25398-6.
A cross-sectional, multicenter survey of the prevalence and risk factors for Long COVID
Waki Imoto[SUP] 1 2 3 [/SUP], Koichi Yamada[SUP] 1 2 3 [/SUP], Ryota Kawai[SUP] 4 [/SUP], Takumi Imai[SUP] 4 [/SUP], Kengo Kawamoto[SUP] 5 [/SUP], Masato Uji[SUP] 5 [/SUP], Hidenori Kanda[SUP] 6 [/SUP], Minoru Takada[SUP] 7 [/SUP], Yoshiteru Ohno[SUP] 8 [/SUP], Hiroshi Ohtani[SUP] 9 [/SUP], Manami Kono[SUP] 10 [/SUP], Atsuhito Hikiishi[SUP] 10 [/SUP], Yosuke Eguchi[SUP] 10 [/SUP], Hiroki Namikawa[SUP] 11 [/SUP], Tomoya Kawaguchi[SUP] 12 [/SUP], Hiroshi Kakeya[SUP] 13 14 15 16 [/SUP]
Affiliations
- PMID: 36575200
- DOI: 10.1038/s41598-022-25398-6
Abstract
Long-term sequelae of the coronavirus disease (COVID-19) constitute Long COVID. Although Long COVID has been reported globally, its risk factors and effects on quality of life (QOL) remain unclear. We conducted a cross-sectional study using questionnaires and electronic medical records of COVID-19 patients who were diagnosed or hospitalized at five facilities in Japan. Responses were obtained from 285 out of 1,150 patients. More than half of the participants reported Long COVID symptoms of varying severity 1 year after COVID-19. Common sequelae included fatigue, dyspnea, alopecia, concentration problems, memory problems, sleeplessness, and joint pain, which often significantly reduced their QOL. COVID-19 severity was strongly associated with sputum production, chest pain, dyspnea, sore throat, and diarrhea, but not with fatigue, dysgeusia, anosmia, alopecia, and sleeplessness. Fatigue, dysgeusia, anosmia, alopecia, and sleeplessness affected the QOL among participants with asymptomatic or mild COVID-19 during the acute phase. Moreover, these sequelae persisted for prolonged periods.